Some companies grow by stacking revenue. Others grow by stacking trust, mileage, and scar tissue. Elara Caring was built the second way. 3 regional operators, decades of home-based care, stitched together in 2018 not for scale theater, but because the math of dignity only works when care actually shows up. That history matters today, because the next chapter is about pressure, not polish.
On February 2, 2026, Elara Caring announced a strategic investment from Ares Management Corporation and DaVita Inc., structured as convertible preferred shares, with the close expected later in 2026 pending the usual regulators and red tape. Investment amount: unconfirmed. No dollar figure disclosed, which tells you this is not a victory lap. This is a signal. When capital stays quiet, it is usually listening.
Ananth Mohan, CEO, does not talk like a hype merchant, and that is the point. Ananth Mohan and John McMahon, CFO, are steering a business that serves more than 60,000 patients a day across 18 states with roughly 26,000 caregivers logging about 12 million visits a year. That is not a slide deck. That is logistics under gravity. Add Betta, Chief Transformation Officer, driving transformation, Michael Alvarez, CIO, wiring the tech, Kimberly Nystrom, President of Skilled Home Health and Hospice, and Tom Firmani, President of Personal Care Services, running clinical and personal care at scale, and this becomes a systems problem disguised as healthcare.
The Ares and DaVita partnership is about meeting complexity where it lives, literally. The plan to co-develop kidney-specific home-based care is not subtle. Dialysis patients do not need another pamphlet. They need continuity, fewer hospitalizations, and a model that respects time, outcomes, and cost in the same sentence. DaVita brings kidney expertise. Elara Caring brings the front door, the hallway, and the living room.
Technology is not the headline, but it is doing the heavy lifting. ElaraConnect, paired with ServiceNow, Apricot.AI, and CareXM, turns scheduling, documentation, and change-in-condition alerts into something clinicians can actually use without burning daylight. High-tech meets high-touch, because anything else collapses under volume.
Blue Wolf Capital Partners and Kelso & Company backed this platform years before the market remembered home-based care was inevitable. Adam Blumenthal, Chairman, has seen enough cycles to know when patience beats noise. This investment feels like that kind of patience. The kind that assumes care will keep moving home, acuity will keep rising, and the companies that win will be the ones built to absorb reality instead of outrunning it.
